Section 3 of 6
Product information and disease description
94 evidence topics · 53 sources
Product description
Phase of product development
Regulatory status: Under review; NDA resubmitted June 2026 and accepted July 2026
Launch
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Saol Therapeutics
Development code and product name
Dosage forms and strengths
Solution strength
No evidence found.
Material safety data sheet
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
Pharmacologic classification
AHFS classification code
No evidence found.
Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Investigational treatment: clinically limiting toxicity
Neuropathy character, dose dependence, and time to resolution
“DCA therefore appears to induce a dose-dependent, largely reversible, distal peripheral neuropathy that afflicts large and small fibers of motor and sensory nerves and causes both sensory loss and pain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all studies, peripheral neuropathy generally resolved over 6–18 months following dose de-escalation or discontinuation, although in some cases it persisted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neuropathy risk by age
“Clinical descriptions of DCA-induced peripheral neuropathy have emphasized that it is more common and severe in adults than children” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In liver, cytosolic GSTZ1 expression (the dominant cellular fraction) reaches adult levels at around 7 years of age, while the mitochondrial form only reaches maximal expression and activity at around 21 years of age” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This explanation is supported by the finding that DCA clearance is reduced less in children than adults following 6 months DCA treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Special populations
Pregnancy, lactation, and reproductive potential
No evidence found.
Renal impairment: SL1009-specific dosing
No evidence found.
Hepatic impairment: SL1009-specific dosing
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on sodium dichloroacetate
No evidence found.
Effects of sodium dichloroacetate on other drugs
No evidence found.
Dosing and administration
Dosage
Genotype-directed dosing in the phase 3 trial
Companion diagnostic: planned submission pathway
Administration
SL1009 administration relative to food
No evidence found.
Access and distribution
Expanded-access request responsibility
Co-prescribed/Concomitant therapies
Effect of sodium dichloroacetate on quality measures
No evidence found.
Product comparison
Review of investigational dichloroacetate and phenylbutyrate
Place of product in therapy
Disease description
Definition and etiology
Epidemiology
Incidence of Pyruvate dehydrogenase complex deficiency
Prevalence of Pyruvate dehydrogenase complex deficiency
U.S. prevalence estimate
Swedish population-based cohort and birth prevalence
Natural history, survival, and mortality
Natural history and mortality
“39% of these subjects (23/59) have died.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Causes of death included severe lactic acidosis, respiratory failure, and infection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age at death and mortality by sex
“Of these, 91% (21/23) died before age 4 years, 61% (14/23) before 1 year, and 43% (10/23) before 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“56% of males died compared with 25% of females.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neonatal or infant onset of symptoms was associated with poor outcomes. Males with PDHA1 mutations and low fibroblast PDC activity were less likely to survive beyond infancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Swedish population-based cohort: mortality
Additional genotype, phenotype, and natural-history evidence
Pathophysiology
Pathophysiology and disease consequences
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Distribution of intellectual outcomes among survivors
“Of 42 subjects whose intellectual abilities were professionally evaluated, 19% had normal or borderline intellectual ability (CQ/IQ ≥ 70), 10% had mild intellectual disability (ID) (CQ/IQ 55–69), 17% had moderate ID (CQ/IQ 40–54), 24% had severe ID (CQ/IQ 25–39) and 33% had profound ID (CQ/IQ < 25).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average outcome for females was severe-to-profound ID, whereas that of males was mild-to-moderate ID.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 10 subjects who reached age 12 years, 9 had had professional IQ assessments, and only 4 had IQs ≥ 70” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Pyruvate dehydrogenase complex deficiency
Humanistic burden and health-related quality of life
Broader mitochondrial disease review: utility evidence
Economic burden and healthcare resource utilization
Broader mitochondrial-disease population: Ontario, Canada
Broader mitochondrial disease: U.S. healthcare costs
Broader mitochondrial disease: treatment costs in China
Broader mitochondrial disease review: cost evidence
Patient employment: adult PDCD
Economic impact of Pyruvate dehydrogenase complex deficiency on families
Broader mitochondrial disease: Australian household costs
“We estimated total annual average costs at AU$ 112 721 per household.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a large proportion were societal costs (92%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
PDCD-specific household and caregiver costs
No evidence found.
Economic impact of diagnostic testing
Broader mitochondrial and rare disorders: proteomics micro-costing
SL1009 dose-determining genetic test cost
No evidence found.
Approaches to treatment
Current treatment options and standard of care
Ketogenic dietary therapy
Ketogenic diet therapies: International Ketogenic Diet Study Group recommendations
Ketogenic-diet literature review and clinical-practice survey
Reported use of ketogenic diet in a natural-history cohort
“The next most common intervention was dietary, with 60% (35/58) of the subjects reportedly having used a “ketogenic” diet at some time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Altogether, 83% (24/29) of responding families reported that use of a ketogenic diet was “very helpful”, 10% said it was “somewhat helpful”, and 7% reported that it was “not helpful”” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No significant correlation was found between use of ketogenic diets and survival or cognitive function outcomes, which is not surprising since use of ketogenic diets varied by degree of severity, duration, and age of administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ketogenic diet therapy does not reverse prior neurological damage and is not effective in sustaining survival in the most severe cases of PDC deficiency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vitamin and cofactor supplementation
Thiamine supplementation
Reported use of thiamine in a natural-history cohort
“Thiamine was the most frequently employed intervention, with 68% (39/57) of subjects reporting some use.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Doses ranged widely from 25 mg to 2000 mg/day (average dose: 174 mg; median dose: 150 mg/dl).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No subject reportedly had a remarkable beneficial response to thiamine treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rehabilitation and supportive care
Muscle function and rehabilitation
Symptom-directed neurologic therapies
Paroxysmal dystonia
Buffer therapy for acidosis
Correction of acidosis
Genotype-specific metabolic management
DLD-related disease: dietary and acute metabolic management
Limitations of current therapies
Summary
Ketogenic dietary treatment must be individualized because tolerance varies. A clinical-practice review identified 40 studies describing 129 participants, predominantly case reports or case series. A separate treatment scoping review included seven preclinical and ten human studies and concluded that most interventions had not been rigorously investigated. These evidence designs limit the certainty of comparative treatment effects.
Cochrane review: mitochondrial disorders, literature search through July 2011
Natural-history cohort: absence of demonstrated benefit for any intervention
“Five subjects had used DCA, and one family reported that it was “very helpful”.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subjective retrospective assessments of the benefits of these various interventions were most favorable for ketogenic diet treatment, but we cannot confidently determine from these data benefit or lack thereof for any of these interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This retrospective correlation of PDC activity, mutations, and outcomes was not designed to assess whether specific treatments were effective in improving outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
SL1009 is an investigational oral treatment with genotype-directed dosing. In the phase 3 study, participants continued ketogenic diets and other supplements; the available evidence therefore concerns use with background treatment rather than replacement of that care. The application remains under FDA review, with a target action date of December 30, 2026. Expanded access is physician-directed, and the published policy requires that the patient be ineligible for a clinical trial and that a licensed treating physician submit the request.
Heterogeneity of treatment effect
Care management intervention strategies
Paroxysmal dystonia: minimizing provoking stressors
Other product development or post-marketing obligations required by the FDA
Original FDA requirement for additional effectiveness evidence
FDA-requested cardiac electrophysiology evaluation
FDA-requested food-effect evaluation
Subsequent sponsor-reported resubmission pathway
Ongoing post-approval monitoring
Not applicable.